Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eissing

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|December 14, 2017
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-SimChristoph Niederalt, Lars Kuepfer, Juri Solodenko, et al.
Clinical Pharmacokinetics|May 9, 2018
A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of LifeJan-Frederik Schlender, Donato Teutonico, Katrin Coboeken, et al.
Frontiers in Pharmacology|June 30, 2020
Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-SimSumit Basu, Yi Ting Kayla Lien, Valvanera Vozmediano, et al.
Clinical Pharmacokinetics|May 4, 2022
Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKDSebastiaan Camiel Goulooze, Hiddo J L Heerspink, Martijn van Noort, et al.
Clinical Pharmacokinetics|October 5, 2019
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney DiseaseNelleke Snelder, Roland Heinig, Henk-Jan Drenth, et al.
Pediatric Cardiology|May 9, 2024
NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart FailureWalter Schmitt, Christian Diedrich, Taye H Hamza, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 15, 2019
Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and MidazolamHannah Britz, Nina Hanke, Anke-Katrin Volz, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 17, 2017
Current strategies to streamline pharmacotherapy for older adultsJan-F Schlender, Valvanera Vozmediano, Adam G Golden, et al.
Clinical Pharmacokinetics|November 17, 2021
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion CriteriaSebastiaan Camiel Goulooze, Nelleke Snelder, Andreas Seelmann, et al.
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Pharmacokinetics and Pharmacodynamics|December 14, 2017
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-SimChristoph Niederalt, Lars Kuepfer, Juri Solodenko, et al.
Clinical Pharmacokinetics|May 9, 2018
A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of LifeJan-Frederik Schlender, Donato Teutonico, Katrin Coboeken, et al.
Frontiers in Pharmacology|June 30, 2020
Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-SimSumit Basu, Yi Ting Kayla Lien, Valvanera Vozmediano, et al.
Clinical Pharmacokinetics|May 4, 2022
Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKDSebastiaan Camiel Goulooze, Hiddo J L Heerspink, Martijn van Noort, et al.
Clinical Pharmacokinetics|October 5, 2019
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney DiseaseNelleke Snelder, Roland Heinig, Henk-Jan Drenth, et al.
Pediatric Cardiology|May 9, 2024
NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart FailureWalter Schmitt, Christian Diedrich, Taye H Hamza, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 15, 2019
Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and MidazolamHannah Britz, Nina Hanke, Anke-Katrin Volz, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 17, 2017
Current strategies to streamline pharmacotherapy for older adultsJan-F Schlender, Valvanera Vozmediano, Adam G Golden, et al.
Clinical Pharmacokinetics|November 17, 2021
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion CriteriaSebastiaan Camiel Goulooze, Nelleke Snelder, Andreas Seelmann, et al.
Clinical Pharmacology and Therapeutics|February 25, 2021
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart FailureWalter Schmitt, Hauke Rühs, Rolf Burghaus, et al.
Pageof 5